Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy
Movement Disorders · 2025
DOI: 10.1002/mds.70026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, 2025. Verfasst von Andrea Quattrone und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Brain, Supranuclear Palsy, Progressive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Clinical progression rate is the typical primary endpoint measure in progressive supranuclear palsy (PSP) clinical trials.
Objectives
This longitudinal multicohort study investigated whether baseline clinical severity and regional brain atrophy could predict clinical progression in PSP–Richardson's syndrome (PSP‐RS).
Methods
PSP‐RS patients (n = 309) from the placebo arms of clinical trials (NCT03068468, NCT01110720, NCT02985879, NCT01049399) and DescribePSP cohort were included. We investigated associations of baseline clinical and volumetric magnetic resonance imaging (MRI) data with 1‐year longitudinal PSP rating scale (PSPRS) change. Machine learning (ML) models were tested to predict individual clinical trajectories.
Results
PSP‐RS patients showed a mean PSPRS score increase of 10.3 points/yr. The frontal lobe volume showed the strongest association with subsequent clinical progression (β: −0.34, P < 0.001). However, ML models did not accurately predict individual progression rates ( R 2
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, University Hospital, LMU Munich, Munich, Germany.
- Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.
- Neuroscience Research Centre, Magna Graecia University, Catanzaro, Italy.
- Institute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, Germany.
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
- Department of Psychiatry and Neurochemistry, University of Gothenburg, The Sahlgrenska Academy, Institute of Neuroscience and Physiology, Mölndal and Gothenburg, Sweden.
ORCID-Profile: Andrea Quattrone
Zitieren
APA
Quattrone, A., Franzmeier, N., Huppertz, H. J., Seneca, N., Petzold, G. C., Spottke, A., Levin, J., Prudlo, J., Düzel, E., PASSPORT Study Group, the AL‐108‐231 Investigators, the Arise Investigators, the Tauros MRI Investigators, the DESCRIBE‐PSP group, & Höglinger, G. U. (2025). Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy. Movement Disorders. https://doi.org/10.1002/mds.70026
Vancouver
Quattrone A, Franzmeier N, Huppertz HJ, Seneca N, Petzold GC, Spottke A, et al. Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy. Movement Disorders. 2025. doi:10.1002/mds.70026
BibTeX
@article{Quattrone2025,
author = {Quattrone, Andrea and Franzmeier, Nicolai and Huppertz, Hans-Jürgen and Seneca, Nicholas and Petzold, Gabor C and Spottke, Annika and Levin, Johannes and Prudlo, Johannes and Düzel, Emrah and PASSPORT Study Group, the AL‐108‐231 Investigators, the Arise Investigators, the Tauros MRI Investigators, the DESCRIBE‐PSP group, PASSPORT Study Group, the AL‐108‐231 Investigators, the Arise Investigators, the Tauros MRI Investigators, the DESCRIBE‐PSP group and Höglinger, Günter U},
title = {Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy},
journal = {Movement Disorders},
year = {2025},
doi = {10.1002/mds.70026}
}
EUVIMED